NASDAQ gives Cell Therapeutics ($CTIC) another warning

NASDAQ is giving Cell Therapeutics ($CTIC) another 180 days to regain compliance with Nasdaq's $1.00 minimum bid price rule. This is Cell Therapeutics second warning; In early May, Nasdaq notified the company that it was trading below the minimum price and had six months to achieve compliance. The developer's stock has been below the $1 mark since March 22.

Cell Therapeutics was recently hit with an FDA rejection of its drug pixantrone for the treatment of relapsed/refractory aggressive non-Hodgkin's. The FDA rejection was based was the result of questions about whether the drug was effective and concerns that Cell Therapeutics managed to enroll only 140 of a planned 320 patients in the trial. The developer, which is conducting a new trial of the drug, plans to appeal the FDA's decision.

- here's Cell Therapeutics' release

Suggested Articles

Xcovery's ALK inhibitor shrank tumors in 75% of lung cancer patients, compared to 67% for Pfizer's Xalkori, the first FDA-approved drug of that class.

The FDA accepted the regulatory filing for Biogen's once-failed Alzheimer's drug, aducanumab, with plans to decide its fate by March 7, 2021.

Alexion named a chief diversity officer, while COVID-19 vaccine player has two new members of its C-suite.